Santen receives positive CHMP opinion in Europe for Ryjunea for slowing the progression of paediatric myopia
Santen Pharmaceutical Co., Ltd. announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) has granted a positive opinion for Ryjunea (:STN 1012701). Ryjunea is a… read more.
